Small Pharma reports second quarter highlights
LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").
Small Pharma to restate financial statements to reflect IFRS fair value of convertible notes and share options
LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").
13 Oct 21 – KCSA Virtual Investor Conference
10:00 A.M. ET Presentation: Small Pharma’s progress in the development of N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of Major Depressive Disorder Presented by Peter Rands, CEO Investor sign up: Registration link For more information about the conference, or to schedule a one-on-one meeting with Small Pharma’s management team, please contact KCSA Strategic Communications […]
Small Pharma reports first fiscal quarter 2021 highlights
Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“DMT”) therapies, has today published its first quarter results for the three months ended May 31, 2021. A full copy of the results can be found under the Company’s profile on SEDAR at www.sedar.com. Unless otherwise indicated, all currency references are to Canadian dollars.
Small Pharma Inc. to commence trading on the TSX Venture Exchange on May 6, 2021
May 4, 2021 (GLOBE NEWSWIRE) – Vancouver, British Columbia – Small Pharma Inc. (formerly Unilock Capital Corp.) (TSXV: DMT) (the “Company” or “Small Pharma”) is pleased to announce that the common shares in the capital of the Company (the “Common Shares”) will commence trading on the TSX Venture Exchange (the “TSXV”) under the ticker symbol “DMT” at the opening of the market on May 6, 2021.
Small Pharma completes reverse take-over
April 29, 2021 – Vancouver, British Columbia – Small Pharma Inc. (TSXV: DMT) (formerly Unilock Capital Corp.) (the “Company”), announces that it has completed its previously announced acquisition of all of the outstanding shares of Small Pharma Ltd (“Small Pharma”), a neuropharmaceutical company specialised in IP led development of novel treatments for mental health conditions (the “Reverse Takeover”).
UniLock Capital Corp. announces filing statement in connection with Small Pharma Ltd. qualifying transaction
Unilock Capital Corp. (TSXV: UUU.P) (“Unilock” or the “Company”) is pleased to announce that it has received conditional approval from the TSX Venture Exchange (the “TSXV”) for its previously announced Qualifying Transaction (as defined in TSXV Policy 2.4) (the “Transaction”) with Small Pharma Ltd (“Small Pharma”)
UK psychedelics firm Small Pharma raises cash to fund reverse takeover on Toronto Stock Exchange
The company, which is researching the potential of N, N-Dimethyltryptamine (DMT) as a treatment for depression, has raised around C$58mln through a brokered private placement Small Pharma, a British firm specialising in psychedelic drugs, said it has raised C$58mln (£33.5mln) through a financing round to fund a reverse takeover of Canadian capital pool company Unilock […]
Small Pharma Ltd. and Unilock Capital Corp. announce closing of fully subscribed brokered private placement financing
March 10, 2021 – Vancouver, British Columbia – Small Pharma Ltd (“Small Pharma”) and Unilock Capital Corp. (“Unilock”) are pleased to announce the closing of the brokered private placement (the “Financing”) of subscription receipts (the “Subscription Receipts”) of Small Pharma Financing Inc. (“Finco”), a special purpose British Columbia company incorporated solely for the purpose of the Financing, at a price of CAD$0.96 per Subscription Receipt
Amended: Unilock Capital Corp. provides update on proposed acquisition of Small Pharma Ltd. and private placement financings
Unilock Capital Corp. (“Unilock”) is pleased to provide an update on its previously announced qualifying transaction with Small Pharma Ltd (“Small Pharma”).